Merit Medical Systems, Inc. (MMSI)
NEUTRALFundamental
72
Preço
$91.70
Capitalização de Mercado
$5.42B
Parte 1 · Quanto vale a empresa
Visão Geral
Merit Medical Systems, Inc. designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States, China, Japan, Germany, France, the United Kingdom, and internationally. It operates through two segments, Cardiovascular and Endoscopy. The company offers micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention products comprising angiography, drainage, delivery systems, and embolotherapy products; oncology products, such as soft tissue biopsy products and accessories; cardiac intervention products consisting of cardiac access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention products; and spine products, including vertebral augmentation, radiofrequency ablation, and bone biopsy systems. It also provides custom procedural solutions, including critical care products, syringes, manifold kits, and trays and packs; coating services for medical tubes and wires; and sensor components for microelectromechanical systems. In addition, the company offers gastroenterology products, such as esophageal stents, cryoballoon and inflation devices, gauges, and balloon dilators; pulmonary products consisting of laser-cut tracheobronchial stents, and over-the-wire and direct visualization delivery systems; and kits and accessories for endoscopy and bronchoscopy procedures. It sells its products to hospitals, alternate site-based physicians, technicians, and nurses through direct sales force, independent distributors, original equipment manufacturer partners, and custom procedure tray manufacturers. The company exports its products to Canada, Western Europe, Australia, Brazil, Malaysia, South Korea, the United Arab Emirates, India, New Zealand, and South Africa. Merit Medical Systems, Inc. was incorporated in 1987 and is headquartered in South Jordan, Utah.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Balanço & Liquidez
Receita
$1.58B
Últimos 12 meses (até 30/06/2026)
Resultado Líquido
$146M
Últimos 12 meses (até 30/06/2026)
Fluxo de Caixa Livre
$216M
Capital Próprio Total
$1.58B
Passivo Total
$1.10B
Rácio de Liquidez
4.20
Cobertura de Juros
6.34
Dívida/EBITDA
2.66
Resultados Por Ação
Receita & Resultado Líquido
Fluxo de Caixa Livre
Decomposição dos Resultados
Demonstração histórica
Margens ao longo do tempo
A dívida ao longo do tempo
Quanto pesa a dívida
Grelha do crescimento
Crescimento — Receitas
Estimativa de Valor Justo
Valor Justo
$74.50
Preço Atual
$91.70
Margem de Segurança
-23.1%
Intervalo de Valor Justo
$48.43 - $100.58
Métodos de Estimativa
Métricas de Avaliação
Rácio P/E
37.15
ROE
8.1%
Rácio P/B
3.21
P/FCF
26.53
Margem Bruta
49.5%
ROIC
6.1%
Radar de Rentabilidade
Value Creation (Economic Moat)
ROIC
6.1%
WACC
7.3%
ROIC − WACC
-1.2 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Critérios de Análise Fundamental
Aprovado (21)
- EPS shows upward trend
- EPS CAGR 7.91%
- Price CAGR 13.10%
- ROIC 6.1%
- Gross Margin 49.5%
- P/FCF 26.53
- Debt/Equity ratio
- Operating Margin 12.8%
- Positive Free Cash Flow
- Current Ratio
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- ROE 9.1%
- Revenue Growth 5Y 9.5%
- Analyst Consensus 82% Buy
- Earnings Surprise avg 11.9%
- Earnings Quality (OCF/NI) 1.95
- Share Dilution 1.7%
- Net Margin Trend 9.2% vs 8.3%
- Piotroski F-Score 7/9
Reprovado (5)
- P/B Ratio 3.21
- CapEx intensity
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
Indisponível (2)
- Dividend Payout NaN%
- PEG Ratio (need PE > 0 and growth > 0)
Piotroski F-Score
Saúde financeira sólida
Qualidade dos Resultados
Alta qualidade: resultados respaldados por caixa
Diluição de Ações
Número de ações estável
Governação
Equipa Executiva
| Nome | Cargo | Idade |
|---|---|---|
| Ms. Martha Goldberg Aronson | President, CEO & Director | 58 |
| Mr. Raul Parra Jr., CPA | CFO & Treasurer | 46 |
| Mr. Brian G. Lloyd J.D. | Chief Legal Officer & Corporate Secretary | 64 |
| Mr. Michel J. Voigt | Chief Human Resources Officer | 52 |
| Mr. Jason Treft | Chief Information Officer | - |
| Ms. Sarah Comstock | Vice President of Global Communications | - |
| Mr. John Knorpp | Chief Regulatory Affairs Officer | - |
| Mr. Ricardo Alvarez | Managing Director of Operation Merit Medical Tijuana | - |
| Mr. Mark Butler | Executive Vice President of Merit Medical EMEA | - |
| Ms. Alisha Jerauld | Sustainability Council Chair and Vice President of Environment, Social & Governance | - |
Risco de Auditoria
2
Risco do Conselho
2
Risco de Remuneração
1
Risco dos Direitos dos Acionistas
4
Parte 2 · O preço e o momento de entrar
Esta parte não serve para saber se a empresa vale: serve para escolher quando comprá-la, depois que os fundamentos te convenceram. Dentro: análise técnica, potencial, quedas históricas, exposição gama.
Latest News
Recent headlines for MMSI, sourced from Markets Gazette.